Lineage Cell Therapeutics, Inc. (LCTX) shareholders
Close on Nov 13, 2026Market cap $231.31MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Neal C. Bradsher Joint filing with Broadwood Partners, L.P. (23.00%), Broadwood Capital, Inc. (23.00%) | 57,848,357 | 23.10% | 13D (active) amendment | Nov 12, 2025 |
| BlackRock, Inc. | 13,185,489 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Chernett Jorey | 11,445,003 | 5.00% | 13G (passive) | Sep 22, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LCTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Broadwood Capital Inc | 49,560,992 | 19.60% | $64.92M | – | 3.39% |
| BlackRock, Inc. | 13,186,895 | 5.21% | $17.27M | +9,322,138 | 0.00% |
| Vanguard Capital Management LLC | 9,054,918 | 3.58% | $11.86M | +736,233 | 0.00% |
| Defender Capital, LLC. | 6,598,899 | 2.61% | $8.64M | −130,700 | 2.81% |
| Geode Capital Management, LLC | 5,299,457 | 2.10% | $6.94M | +2,776,343 | 0.00% |
| Raffles Associates LP | 5,197,788 | 2.06% | $6.81M | −165,000 | 2.99% |
| Fifth Third Bancorp | 4,600,000 | 1.82% | $6.03M | – | 0.01% |
| Millennium Management LLC | 3,018,567 | 1.19% | $3.95M | −2,542,807 | 0.00% |
| State Street Corp | 2,314,180 | 0.92% | $3.03M | +1,224,069 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,668,629 | 0.66% | $2.19M | +344,471 | 0.00% |
| Northern Trust Corp | 1,656,651 | 0.66% | $2.17M | +1,157,524 | 0.00% |
| Morgan Stanley | 1,471,462 | 0.58% | $1.93M | −397,029 | 0.00% |
| Renaissance Technologies LLC | 1,344,829 | 0.53% | $1.76M | −780,271 | 0.00% |
| Marshall Wace, Llp | 1,282,347 | 0.51% | $1.68M | −1,782,686 | 0.00% |
| Vanguard Portfolio Management LLC | 1,273,311 | 0.50% | $1.67M | New | 0.00% |
| UBS Group AG | 687,051 | 0.27% | $900.04K | −683,410 | 0.00% |
| Red Crane Wealth Management, LLC | 597,263 | 0.24% | $782.42K | – | 0.58% |
| Charles Schwab Investment Management Inc | 577,435 | 0.23% | $756.44K | +447,511 | 0.00% |
| Barclays PLC | 508,668 | 0.20% | $666.35K | +115,359 | 0.00% |
| Squarepoint Ops LLC | 444,774 | 0.18% | $582.65K | +301,584 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 131 | 117M | 46.1% | 35 / 25 | 30 / 32 | 21M | 16M |
| Q1 2026 | 130 | 112M | 44.2% | 24 / 37 | 26 / 12 | 27M | 2M |
| Q4 2025 | 123 | 102M | 40.2% | 25 / 30 | 28 / 12 | 18M | 4M |
| Q3 2025 | 112 | 88M | 34.8% | 17 / 23 | 33 / 34 | 3M | 13M |
| Q2 2025 | 129 | 98M | 38.8% | 35 / 23 | 35 / 32 | 11M | 22M |
| Q1 2025 | 127 | 109M | 43.3% | 19 / 38 | 22 / 16 | 17M | 15M |
| Q4 2024 | 126 | 107M | 42.4% | 28 / 37 | 17 / 13 | 21M | 9M |
| Q3 2024 | 114 | 95M | 37.7% | 9 / 28 | 25 / 7 | 12M | 7M |
| Q2 2024 | 113 | 100M | 39.4% | 8 / 35 | 26 / 11 | 8M | 4M |
| Q1 2024 | 116 | 95M | 37.6% | 15 / 30 | 31 / 12 | 20M | 2M |
| Q4 2023 | 115 | 77M | 30.4% | 15 / 27 | 25 / 4 | 4M | 2M |
| Q3 2023 | 104 | 76M | 29.9% | 6 / 26 | 24 / 9 | 3M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
53 funds held LCTX in Q2 2026, 79% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LCTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,907,404 | 2.34% | $7.74M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,159,208 | 1.64% | $5.45M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,962,901 | 1.17% | $3.88M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,994,857 | 0.79% | $2.15M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,730,644 | 0.68% | $2.27M | 0.01% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,322,034 | 0.52% | $1.73M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,196,937 | 0.47% | $1.59M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 617,154 | 0.24% | $808.47K | 0.05% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 447,526 | 0.18% | $483.33K | 0.01% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 438,359 | 0.17% | $583.02K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 346,304 | 0.14% | $460.58K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 344,484 | 0.14% | $451.27K | 0.01% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 245,384 | 0.10% | $265.01K | 0.01% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 221,000 | 0.09% | $289.51K | 0.20% | Jun 30, 2026 |
| EQ/2000 Managed Volatility Portfolio | 193,554 | 0.08% | $253.56K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Brian M. Culley | President and CEO, Director | 255,516 | 0.10% | Mar 12, 2026 |
| Jill Ann Howe | Chief Financial Officer | 25,500 | 0.01% | Mar 6, 2026 |
| George A. Samuel III | General Counsel and Secretary | 31,063 | 0.01% | Mar 6, 2026 |
| Anula Jayasuriya | Director | 10,000 | 0.00% | Jul 2, 2026 |
| Dipti Amin | Director | 35,000 | 0.01% | Jul 2, 2026 |
| Deborah J. Andrews | Director | 34,720 | 0.01% | Jul 2, 2026 |
| Angus C. Russell | Director | 92,220 | 0.04% | Jul 2, 2026 |
| Neal C. Bradsher | Director, 10% owner | 104,136,455 | 41.18% | Jul 2, 2026 |
| Michael H. Mulroy | Director | 298,555 | 0.12% | Jul 2, 2026 |
| Broadwood Partners, L.P. | Director, 10% owner | 83,332,510 | 32.95% | Jan 28, 2025 |
| Capital Inc Broadwood | 10% owner | 99,121,984 | 39.19% | Jan 28, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brian M. Culley President and CEO, Director | Mar 12, 2026 | Buy | +15,000 | $1.63 | $24.45K | 255,516 |
| George A. Samuel III General Counsel and Secretary | Feb 11, 2026 | Tax withholding | −2,502 | $1.80 | $4.50K | 31,063 |
| George A. Samuel III General Counsel and Secretary | Feb 11, 2026 | Option exercise | +6,075 | – | – | 33,565 |
| Brian M. Culley President and CEO, Director | Feb 11, 2026 | Tax withholding | −12,869 | $1.80 | $23.16K | 240,516 |
| Brian M. Culley President and CEO, Director | Feb 11, 2026 | Option exercise | +31,250 | – | – | 253,385 |
| George A. Samuel III General Counsel and Secretary | Dec 19, 2025 | Tax withholding | −65 | $1.68 | $109 | 27,490 |
| George A. Samuel III General Counsel and Secretary | Dec 19, 2025 | Award | +1,735 | – | – | 27,555 |
| Brian M. Culley President and CEO, Director | Dec 19, 2025 | Tax withholding | −334 | $1.68 | $561 | 222,135 |
| Brian M. Culley President and CEO, Director | Dec 19, 2025 | Award | +8,925 | – | – | 222,469 |
| George A. Samuel III General Counsel | Feb 11, 2025 | Tax withholding | −2,440 | $0.65 | $1.59K | 25,820 |
| George A. Samuel III General Counsel | Feb 11, 2025 | Option exercise | +6,076 | – | – | 28,260 |
| Brian M. Culley President and CEO, Director | Feb 11, 2025 | Tax withholding | −12,547 | $0.65 | $8.16K | 213,544 |
| Brian M. Culley President and CEO, Director | Feb 11, 2025 | Option exercise | +31,249 | – | – | 226,091 |
| Capital Inc Broadwood 10% owner | Jan 27, 2025 | Buy | +0 | – | – | 49,560,992 |
| Capital Inc Broadwood 10% owner | Jan 27, 2025 | Buy | +7,894,737 | $0.76 | $6.00M | 49,560,992 |
| Jill Ann Howe Chief Financial Officer | Nov 26, 2024 | Buy | +15,000 | $0.59 | $8.85K | 25,500 |
| George A. Samuel III General Counsel | Nov 26, 2024 | Buy | +15,000 | $0.60 | $9.00K | 22,184 |
| Michael H. Mulroy Director | Nov 22, 2024 | Buy | +40,000 | $0.57 | $22.80K | 298,555 |
| Brian M. Culley President and CEO, Director | Nov 21, 2024 | Buy | +40,000 | $0.60 | $24.00K | 194,842 |
| Jill Ann Howe Chief Financial Officer | Aug 16, 2024 | Buy | +10,500 | $0.89 | $9.35K | 10,500 |
| Brian M. Culley President and CEO, Director | May 24, 2024 | Buy | +10,000 | $1.05 | $10.50K | 154,842 |
| George A. Samuel III General Counsel/Secretary | Feb 11, 2024 | Tax withholding | −2,490 | $1.08 | $2.69K | 7,184 |
| George A. Samuel III General Counsel/Secretary | Feb 11, 2024 | Option exercise | +6,076 | – | – | 9,674 |
| Brian M. Culley President and CEO, Director | Feb 11, 2024 | Tax withholding | −12,806 | $1.08 | $13.83K | 144,842 |
| Brian M. Culley President and CEO, Director | Feb 11, 2024 | Option exercise | +31,249 | – | – | 157,648 |
| Don M. Bailey Director | Feb 8, 2024 | Buy | +96,155 | $1.04 | $100.00K | 158,801 |
| Broadwood Partners, L.P. Director, 10% owner | Feb 6, 2024 | Buy | +6,730,770 | $1.04 | $7.00M | 41,666,255 |
| Broadwood Partners, L.P. Director, 10% owner | Feb 6, 2024 | Buy | +0 | – | – | 41,666,255 |
| Anula Jayasuriya Director | Dec 29, 2023 | Buy | +10,000 | $1.09 | $10.90K | 10,000 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Feb 11, 2023 | Tax withholding | −5,310 | $1.35 | $7.17K | 7,710 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Feb 11, 2023 | Option exercise | +13,020 | – | – | 13,020 |
| Brian M. Culley President and CEO, Director | Feb 11, 2023 | Tax withholding | −12,744 | $1.35 | $17.20K | 126,399 |
| Brian M. Culley President and CEO, Director | Feb 11, 2023 | Option exercise | +31,249 | – | – | 139,143 |
| George A. Samuel III General Counsel/Secretary | Feb 11, 2023 | Tax withholding | −2,478 | $1.35 | $3.35K | 3,598 |
| George A. Samuel III General Counsel/Secretary | Feb 11, 2023 | Option exercise | +6,076 | – | – | 6,076 |
| Alfred D. Kingsley Director | Dec 1, 2022 | Gift | −25,000 | – | – | 5,430,545 |
| Brian M. Culley President and CEO, Director | Jun 30, 2022 | Tax withholding | −5,343 | $1.58 | $8.44K | 107,894 |
| Brian M. Culley President and CEO, Director | Jun 30, 2022 | Option exercise | +15,450 | – | – | 113,237 |
| Brian M. Culley President and CEO, Director | Mar 31, 2022 | Option exercise | +15,450 | – | – | 96,730 |
| Brian M. Culley President and CEO, Director | Mar 31, 2022 | Tax withholding | −5,343 | $1.54 | $8.23K | 91,387 |
| Brian M. Culley President and CEO, Director | Mar 31, 2022 | Buy | +6,400 | $1.53 | $9.79K | 97,787 |
| Dipti Amin Director | Mar 28, 2022 | Buy | +35,000 | $1.63 | $57.05K | 35,000 |
| Brian M. Culley President and CEO, Director | Mar 25, 2022 | Buy | +5,250 | $1.38 | $7.24K | 81,280 |
| Neal C. Bradsher Director, 10% owner | Mar 25, 2022 | Buy | +0 | – | – | 34,935,485 |
| Neal C. Bradsher Director, 10% owner | Mar 25, 2022 | Buy | +470,000 | $1.44 | $676.80K | 34,935,485 |
| Neal C. Bradsher Director, 10% owner | Mar 24, 2022 | Buy | +0 | – | – | 34,465,485 |
| Neal C. Bradsher Director, 10% owner | Mar 24, 2022 | Buy | +200,000 | $1.42 | $284.00K | 34,465,485 |
| Michael H. Mulroy Director | Mar 24, 2022 | Buy | +7,000 | $1.40 | $9.80K | 258,555 |
| Neal C. Bradsher Director, 10% owner | Mar 23, 2022 | Buy | +260,106 | $1.37 | $356.35K | 34,265,485 |
| Neal C. Bradsher Director, 10% owner | Mar 23, 2022 | Buy | +0 | – | – | 34,265,485 |
| Brian M. Culley President and CEO, Director | Dec 31, 2021 | Tax withholding | −5,343 | $2.45 | $13.09K | 76,030 |
| Brian M. Culley President and CEO, Director | Dec 31, 2021 | Option exercise | +15,450 | – | – | 81,373 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 29, 2021 | Sale | −28,445 | $2.44 | $69.41K | 0 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 29, 2021 | Sale | −9,250 | $2.49 | $23.03K | 28,445 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 29, 2021 | Option exercise | +9,250 | $0.69 | $6.38K | 37,695 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 28, 2021 | Sale | −501,588 | $2.45 | $1.23M | 28,445 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 28, 2021 | Option exercise | +79,689 | $1.14 | $90.85K | 530,033 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 28, 2021 | Option exercise | +236,899 | $2.11 | $499.86K | 450,344 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 28, 2021 | Option exercise | +185,000 | $0.69 | $127.65K | 213,445 |
| Alfred D. Kingsley Director | Dec 1, 2021 | Gift | −14,700 | – | – | 5,455,545 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lineage Cell Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,826 shares on Oct 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Don M. Bailey Director | Sep 24, 2025 | 60,000 | $96.02K | Sep 24, 2025 | Stock Option Exercise |
| Don M. Bailey Director | Sep 10, 2025 | 80,000 | $97.47K | Sep 10, 2025 | Stock Option Exercise |
See a number that looks wrong?